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Abstract 25 
Background: There are limited published data on the analgesic efficacy of 26 
paracetamol/codeine in dogs. 27 
Methods: Prospective, randomized, blinded, positive-controlled clinical trial with 70 28 
dogs (paracetamol/codeine, n = 46; meloxicam, n = 24) undergoing surgery. Drugs 29 
were administered orally two hours before and for 48 hours after surgery at the 30 
licensed dose. Anaesthesia was standardised. Dogs received buprenorphine 6- hourly 31 
for the first 24 hours after surgery. Outcome assessments were made pre-trial and at 32 
regular intervals up to 48 hours after extubation and comprised the Glasgow 33 
Composite Measure Pain Score (GCMPS-SF), visual analogue scale for sedation and 34 
inflammation and mechanical nociceptive threshold (MNT). Non-inferiority of 35 
paracetamol/codeine compared with meloxicam was defined using a non-inferiority 36 
margin (Δ) against the 95% confidence interval of the difference between the treatment 37 
means.   38 
Results: Pain scores were low in both treatment groups. With the exception of MNT 39 
all upper 95% confidence intervals for the differences between outcome variable 40 
treatment means were within + Delta for each variable, establishing non-inferiority for 41 
each outcome variable.  42 
Conclusions: Paracetamol/codeine is a useful peri-operative analgesic that within the 43 
context of the peri-operative analgesia regimen studied (methadone premedication, 44 
buprenorphine for the 1st 24 hours after surgery) shows non-inferiority to the NSAID 45 
meloxicam. 46 
 47 
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Introduction 50 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used extensively in human and 51 
veterinary medicine due to their antipyretic, anti-inflammatory and analgesic properties 52 
[1]. Along with opioids, they are considered one of the best classes of analgesic drugs 53 
at preventing postoperative pain and have a clear role in multimodal analgesia. 54 
Meloxicam, available as both oral and injectable solutions, is approved for use in dogs 55 
and has proven efficacy [1,2]. Despite paracetamol’s (acetaminophen’s) wide use in 56 
human medicine [3] and its toxicity being well established, its mechanism of action is 57 
not totally understood. Similarly to other non-steroidal anti-inflammatory drugs, 58 
paracetamol is able to inhibit prostaglandin synthesis from arachidonic acid by 59 
inhibiting cyclo-oxygenase enzymes (COX). This inhibition is likely to happen both 60 
peripherally and centrally resulting in both an analgesic and antipyretic effect [4]. 61 
Paracetamol has also been suggested to be a centrally acting TRPV1 receptor agonist 62 
[5]. Pardale-V ® is the oral preparation of paracetamol licensed for use in dogs in the 63 
UK. The formulation also contains codeine, which is an opioid. However the dose of 64 
codeine in Pardale – V ® is very low with a ratio of 400 mg of paracetamol to 9 mg of 65 
codeine in a single tablet. Oral codeine is rapidly metabolized to produce codeine-6-66 
glucuronide in dogs [6]. Codeine-6-glucuronide has been shown to have 67 
antinociceptive effects in rats [7] although the effects of codeine-6-glucuronide on 68 
antinociception in dogs are unknown.  69 
 70 
Non-inferiority testing is designed to test whether a novel therapy has non-inferior 71 
efficacy to the ones already in use. In order to determine non-inferiority an equivalence 72 
margin, or Delta, must be determined, which defines a range of values for which 73 
efficacies are close enough to be considered non-inferior to each other. The margin is 74 
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the maximally acceptable clinical difference that is accepted in return for the secondary 75 
benefits of the new therapy. 76 
 77 
In veterinary medicine, despite being licensed to control acute pain in dogs there are 78 
a paucity of data regarding paracetamol/codeine’s analgesic efficacy and the 79 
incidence of adverse effects is unknown. The aim of this study was to investigate 80 
analgesic efficacy of oral paracetamol/codeine (Pardale-V ®), at the licensed dose, in 81 
dogs undergoing surgery by comparison with meloxicam, which is licensed for dogs 82 
and has proven efficacy for soft tissue and orthopaedic peri-operative pain relief.  83 
 84 
In this non-inferiority trial we hypothesized that paracetamol/codeine, at the licensed 85 
dose, has analgesic efficacy that is not inferior to meloxicam in dogs undergoing 86 
surgery.  87 
 88 
Materials and Methods 89 
Animals 90 
Client owned dogs presented for soft tissue and orthopaedic surgery were recruited. 91 
Inclusion criteria were dogs older than two months of age, of any breed or sex and 92 
suitable for treatment with a non-steroidal anti-inflammatory agent. Exclusion criteria 93 
were dogs receiving any NSAID within the 48 hours before induction of anaesthesia, 94 
opioids within 12 hours before induction of anaesthesia or any history of diarrhoea, 95 
vomiting, polyuria/polydipsia, a hepatic or haemostatic condition suggestive of 96 
reduced blood clotting efficacy.  97 
 98 
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Case recruitment 99 
Cases were recruited at two centres; soft tissue cases were recruited at Langford Vets, 100 
University of Bristol and orthopaedic cases were recruited at St. Davids Veterinary 101 
Group, Exeter. One investigator, a registered veterinarian unaware of treatment 102 
allocation recruited cases and collected all data. Written informed owner consent was 103 
obtained from the owners of all dogs recruited to the study. The study was approved 104 
by the University of Bristol ethical review committee (VIN/13/042). 105 
All dogs had a fasting period of 12 hours. Water was allowed until the premedication 106 
was administered. Baseline assessments were made before first drug administration 107 
given by a registered veterinary nurse; two to four hours later anaesthesia was 108 
induced by a veterinary surgeon.  109 
 110 
 111 
Treatments 112 
At the time of presentation the dogs were randomly allocated into two groups: 113 
paracetamol/codeine (P group) or meloxicam (M group). Randomisation was achieved 114 
using the website https://www.random.org/ to generate a series of integers, with even 115 
integers assigned to the P group and odd integers assigned to the M group. An 116 
adjustment was made where necessary to this allocation to ensure that the appropriate 117 
number of cases were assigned to each group (i.e. cases were allocated in a 2:1 ratio 118 
for the P and M group respectively). Allocation to a 2:1 ratio is a study design that has 119 
been used previously in studies evaluating the efficacy of robenacoxib for the 120 
management of acute and chronic pain [8, 9]. The rationale for this distribution of cases 121 
is that it assigns a higher number of cases to the “new” treatment under test so that 122 
any adverse effects associated with the new treatment are more likely to be detected.  123 
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Dogs allocated to group P received oral paracetamol/codeine (Pardale-V ®, Dechra) 124 
at the licensed dose (33 mg kg-1) at least two hours before induction of anaesthesia. 125 
Administration of oral paracetamol/codeine was repeated every 8 hours for up to 48 126 
hours after extubation time (T0). Dogs allocated to group M received oral meloxicam 127 
(Metacam ®, Boehringer Ingelheim) at the licensed dose (loading dose: 0.2 mg kg-1) 128 
at least two hours before induction of anaesthesia. Administration of meloxicam was 129 
repeated, at the maintenance dose (0.1 mg kg-1) every 24 hours for up to 48 hours 130 
after T0. At the end of the study, 48 hours after T0 all dogs were treated with meloxicam. 131 
Dogs allocated to the group P received the first dose of meloxicam, at the maintenance 132 
dose, eight hours after the last dose of paracetamol/codeine. See CONSORT Flow 133 
Diagram MURRELL as Supplementary Figure 1 for a schematic outline of enrolment 134 
of dogs, treatment allocation and follow-up. 135 
 136 
Outcome assessments  137 
Study outcome assessments for pain, inflammation, sedation and tolerability were 138 
made by the single, blinded assessor. Requirement for rescue analgesia was also 139 
recorded. 140 
 141 
The first outcome assessment was performed at baseline, before first test drug 142 
administration followed by ten time points. The second outcome assessment was 143 
carried out at T2, (2 hours after extubation which was counted as T0); T4; T6; T8; T12; 144 
T24; T28; T32; T36; T48, respectively 2, 4, 6, 8, 12, 24, 28, 32, 36 and 48 hours after 145 
extubation time. 146 
 147 
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Outcome assessments included were the Glasgow Composite Pain Score – Short 148 
Form (GCMPS-SF) [10], as the primary efficacy endpoint, the mechanical nociceptive 149 
threshold (MNT), the visual analogue scale for inflammation (VASi) and the visual 150 
analogue scale for sedation (VASs). At each time point the first assessment performed 151 
was the GCMPS-SF, followed by the VASi, VASs and MNT.  152 
 153 
Pain was assessed using the GCMPS-SF. The GCMPS-SF was carried out as 154 
described on the questionnaire and after completing the assessment, the pain score 155 
was considered as the sum of the rank scores. 156 
 157 
Inflammation was assessed with the VASi, using a line between 0 and 100 mm, where 158 
0mm was considered no inflammation and 100mm major inflammation. The surgical 159 
wound was observed, checked with light touch and evaluated for local heat, swelling 160 
and redness. 161 
 162 
Sedation of each patient was assessed using the VASs; a line between 0 and 100 mm 163 
where 0 mm was a fully awake patient and 100 mm was an unconscious patient. 164 
Sedation assessment was based on the subjective evaluation of the dog’s 165 
consciousness, behavior and attitude.  166 
 167 
MNT was measured using a pressure algometer (PRoD Topcat Metrology Ltd) as a 168 
biomarker of secondary hyperalgesia, defined as increased pain from a stimulus that 169 
would normally be painful in the area of surrounding uninjured tissue. The PRoD, fitted 170 
with a 2 mm tip, was applied perpendicular to the skin 2 cm around the surgical wound, 171 
which is an expected area of secondary hyperalgesia adjacent to the surgical site. 172 
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Increasing force (at 2 N sec-1) was applied until the animal demonstrated any 173 
behaviour indicating conscious perception of pain, such as flinching, growling or trying 174 
to escape from the stimulus with a cut off of 18.5 Newtons. Each assessment was 175 
performed with the dog lying down and each reading was considered the average of 176 
three measurements made at two-minute intervals. Dogs received training and 177 
familiarization with the MNT procedure, assessors and the environment prior to the 178 
start of the study to minimize the potential effect of the researcher presence and the 179 
testing procedure on thresholds [11]. 180 
 181 
Tolerability was also assessed. Any adverse effects attributable to test drug 182 
administration were recorded any time during the study period to compare the 183 
incidence between groups. If adverse effects were detected in any animal (e.g. 184 
vomiting, diarrhoea, regurgitation), administration of the test drug was stopped, 185 
analgesia was continued with buprenorphine, and the dog was withdrawn from the 186 
study. Data up until the dog was withdrawn from the study were included in the 187 
analysis.  188 
 189 
In orthopaedic patients, when it was not possible to assess for inflammation or perform 190 
MNT at any time point, due to a cast or bandage covering the surgical site, the 191 
assessments were carried out excluding only these two methods until the bandage 192 
was removed and it was possible to perform them again.  193 
 194 
At relevant time points the assessments were made before drug administration. 195 
Adverse events and requirement for rescue analgesia were recorded any time during 196 
study period. 197 
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 198 
Anaesthesia 199 
The anaesthetic protocol was standardized. All dogs received premedication with 200 
methadone 0.3 mg kg-1 IM or IV alone or in combination with acepromazine 0.010 to 201 
0.060 mg kg-1 (ACP, Novartis Animal Health) or midazolam 0.10 to 0.20 mg kg-1 202 
(Hypnovel, Roche Products Limited). Anaesthesia was induced using propofol to effect 203 
1 to 4 mg kg-1 injected intravenously (Propofol-®Lipuro Vet, Virbac). Isoflurane (IsoFlo, 204 
Abbott Animal Health) vaporized in oxygen was used for maintenance of anaesthesia. 205 
Intra-operatively, if any cardiovascular response to surgery occurred, a fentanyl bolus 206 
(1-5 µg kg-1) was administered and the total dose was recorded. Adequate depth of 207 
anaesthesia was monitored based on the presence or absence of a palpebral reflex, 208 
the degree of jaw tone and position of the eye. A registered veterinary nurse or 209 
veterinary surgeon monitored anaesthesia continuously in every patient, recording 210 
every 5 minutes HR, RR, temperature, the flow rate of oxygen, the vaporiser setting 211 
of isoflurane, SpO2 and ETCO2. Extubation was performed when the dog had regained 212 
a swallowing reflex. 213 
 214 
Analgesia 215 
In addition to the test drug all dogs were treated with buprenorphine (Vetergesic, 216 
Alstoe Animal Health) at a dose of 20 µg kg-1 IV for the first 24 hours after surgery. 217 
The first dose was administered at T0 and repeated every 6 hours up to, and excluding 218 
T24. At T24 buprenorphine administration was stopped until end of the study (T48).  219 
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 220 
Rescue analgesia 221 
Methadone 0.3 mg kg-1 IV was selected to provide rescue analgesia when required. It 222 
was administered when the assessor defined the GCMPS-SF equal to, or more than, 223 
5/20 or 6/24 in a patient, for non-ambulatory or ambulatory patients respectively [10]. 224 
A repeated pain assessment, using GCPS-SF was performed 15-30 minutes after 225 
rescue administration. When GCPS-SF was below the defined range the dog returned 226 
to the predefined buprenorphine scheme. If a first dose of methadone was inadequate, 227 
administration was repeated as necessary based on the defined criteria (until the 228 
GCPS-SF was below 5/20 or 6/24). The subsequent analgesic protocol for each 229 
patient, with methadone or buprenorphine, was at discretion of the investigator in 230 
collaboration with the clinician and adapted to the individual need of the patient.  231 
 232 
Statistical analysis 233 
For the dogs that needed rescue analgesia the last observation carried forward 234 
(LOCF) was applied. Non-inferiority of paracetamol/codeine compared with 235 
meloxicam was defined using a non-inferiority margin (Δ) against the 95% 236 
confidence interval of the difference between the treatment means.  The non-237 
inferiority margin defines how much the control treatment may exceed the new 238 
treatment with the new treatment still being considered non-inferior to the control. 239 
The non-inferiority margin for the primary efficacy endpoint, the GCMPS-SF, was 240 
defined as 3; for the MNT all values were converted to a percentage of the baseline 241 
value for an individual dog and Delta was defined as a change of 10% from baseline; 242 
for the VASs and VASi it was 20 mm. A useful guide to non-inferiority testing can be 243 
found in [12]. An important aspect of this non-inferiority study is the determination of 244 
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Delta. In this study Delta values were selected that the authors thought were 245 
clinically relevant i.e. a difference of this value would represent a clinically relevant 246 
difference between the two drugs. This approach was selected because there are no 247 
established values for Delta for the outcome measures used in this study.  Therefore 248 
3 was chosen as a clinically relevant difference in the GCMP-SF. This difference was 249 
considered likely to “push” a non painful dog above the intervention threshold for the 250 
GCMP-SF so that rescue analgesia was required. 20 mm was chosen as a clinically 251 
relevant difference in the VASs and VASi because if the 100 mm line of the VAS is 252 
divided into 5 categories of sedation or inflammation (none, mild, moderate, severe 253 
and very severe) a difference of 20 mm is enough to cause a transition from one 254 
category to another and therefore was deemed to be clinically relevant. For the MNT, 255 
a clinically relevant difference was decided as 10%. This was decided because small 256 
differences in MNT are likely to reflect differences in the occurrence of secondary 257 
hyperalgesia between groups. 258 
 259 
As the data were in the form of repeated measurements, the area under the curve 260 
(AUC) was calculated for each outcome measure. Only the area from T2 to T48 was 261 
considered, and dogs with any missing values for a variable were dropped from the 262 
analysis of that variable. Only T2 to T24 were considered for VASs as all values after 263 
24 hours were 0. The AUC was then divided by the number of hours monitored to give 264 
an average score for any one hour, thus rescaling the AUC to the original 265 
measurement scale, and this value was used as the outcome measure. It is of interest 266 
to follow the time course of each treatment and so graphs of each outcome measure 267 
over time are presented below.  268 
 269 
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A two-sample t-test was used to check whether a difference in age and weight had 270 
arisen between the treatment groups despite randomisation. A Chi-square test was 271 
used to verify if there was any association between breed, sex and type of surgery 272 
and treatment group.  273 
 274 
Summary statistics and statistical analyses were performed using SPSS statistics 25 275 
(IBM, New York). Individual statistical independent two-sided t-tests were performed 276 
at significance level alpha = 0.05 and 95% confidence intervals for the differences 277 
between treatments were also produced. Inspection of histograms showed that data 278 
were approximately normally distributed, with the exception of VASs scores which 279 
required a log normal transformation, following the addition of 0.1 to avoid scores of 280 
zero, thus a standard approach to non-inferiority testing based on the normal 281 
probability distribution was justified.  A Levene’s test was used to test for the t-test’s 282 
assumption of equality of variances treatment groups.  The results from the non-283 
inferiority analyses are presented graphically and show the mean difference between 284 
the average score in any one hour together with a 95% confidence interval for the 285 
difference. Broken, vertical lines on the graphs show ± Delta. The difference was 286 
calculated as Paracetamol/codeine treatment minus Meloxicam treatment. Thus, with 287 
the exception of MNT, as superior treatments have lower values, negative values for 288 
the difference indicate greater efficacy with Paracetamol/codeine and positive values 289 
greater efficacy with Meloxicam. For non-inferiority to be shown, the upper 95% 290 
confidence limit for the difference should be below + Delta, whilst for MNT the lower 291 
confidence interval would need to be greater than - Delta. 292 
 293 
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There were no prior data on which to base a power analysis for this study. The study 294 
size was limited by the duration of the student’s (MP) appointment and the number of 295 
suitable dogs presenting at the clinics. It was anticipated that between 50 to 100 dogs 296 
could be recruited within the time available.  297 
 298 
Results 299 
Animals 300 
Seventy client owned dogs were recruited from clinical cases undergoing soft tissue 301 
or orthopaedic surgery. Fifty nine orthopaedic cases were recruited from St David’s 302 
Veterinary Group, Exeter and 11 soft tissue cases from Langford Vets, University of 303 
Bristol. No cases were excluded from recruitment based on the exclusion criteria. Soft 304 
tissue procedures were performed by an ECVS or RCVS specialist as primary surgeon 305 
or by a surgery resident under direct supervision of the specialist. All orthopaedic 306 
procedures were performed by a single experienced surgeon, an RCVS advanced 307 
practitioner. Twenty four dogs were allocated to group M and 46 dogs to group P. Due 308 
to missing data points within the repeated measurements 70, 70, 41 and 41 dogs were 309 
available for the analysis of GPCS, VASs, VASi and MNT, respectively. For VASi there 310 
were 14 dogs in the meloxicam group and 27 dogs in the paracetamol group for which 311 
data were available. For MNT there were 11 dogs in the meloxicam group and 30 dogs 312 
in the paracetamol group. 313 
 314 
Demographic data 315 
The mean  SD age of the dogs enrolled onto the study was 51  38 months, with a 316 
mean age of 51  44 months in group M and 51  35 months in group P. There was 317 
no significant difference in age between groups (p=0.96). The mean  SD body weight 318 
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of all dogs enrolled onto the study was 26.0  14.7 kg, with a mean of 28.6  14.3 kg 319 
in group M and 24.7  14.9 kg in group P, with no significant difference in bodyweight 320 
between groups (p=0.29).  There was no significant difference in the gender 321 
distribution between groups (p=0.78). A variety of breeds were represented (38), the 322 
most represented breed was Labradors (6 in each group), and there was no significant 323 
difference in the distribution of breeds between groups. Twenty-two different surgical 324 
procedures were included (Table 1), with tibial tuberosity advancement (TTA) being 325 
the most frequent, in 19 cases (8 (33%) in group M and 11 (24%) in group P), followed 326 
by total hip replacement (THR), in 16 cases (3 (12.5%) in group M and 13 (28%) in 327 
group P). There was no significant difference in the type and number of surgical 328 
procedures between groups. In total three dogs received midazolam for premedication 329 
(one in the meloxicam group and 2 in the paracetamol group), the rest of the dogs 330 
were premedicated with acepromazine. 331 
Table 1: A list of the different surgical procedures carried out in the meloxicam and 332 
paracetamol/codeine groups. 333 
Procedure Meloxicam Group Paracetamol/codeine 
Group 
Tibial Tuberosity 
Advancement 
8 11 
Open stifle lavage 1  
MPL 1 3 
ED 3 2 
Ulnar osteotomy 1 4 
Total hip replacement 3 14 
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Achilles Tendon Repair 1 1 
Femoral Head and Neck 
Excision 
1 1 
Dermoid sinus exploration 1  
Brachycephalic 
obstructive airway 
syndrome surgery 
(staphylectomy & 
alarplasty) 
1 2 
Hindlimb soft tissue 
sarcoma removal 
1  
Partial maxillectomy 1  
Laparoscopic 
ovariohysterectomy 
1  
Fracture repair  1 
Stabilisation of a shoulder 
luxation 
 1 
Anal sacculectomy  1 
Castration  1 
Total ear canal ablation  1 
Facial biopsy  1 
Placement of a urethral 
hydraulic occluder 
 1 
Laryngeal tieback  1 
 334 
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Test treatments 335 
There were no significant differences between groups in the baseline measurements 336 
of GCMPS-SF (p=0.9), MNT (p=0.70), VASs and VASi (p=0.78). 337 
 338 
The primary efficacy endpoint was the GCMPS-SF score. From the 2 hour time point 339 
post extubation all dogs were ambulatory, therefore the GCMPS-SF was scored out 340 
of 24. Pain was well controlled in most cases in the post-operative period (Figure 1).   341 
 For MNT, the pattern after surgery was as expected, with a decrease of the MNT after 342 
surgery and an increase over time for both drugs (Figure 2). Changes in sedation and 343 
inflammation over time in both groups are shown in Figures 3 and 4. 344 
The results of the non-inferiority analysis for all the outcome variables are summarised 345 
in Table 2 and shown graphically in Figure 5. From the Levene's test we concluded no 346 
meaningful differences in variances between groups (see Table 2 for p values). A 2-347 
sided t-test showed no significant difference between treatment means for any of the 348 
outcome variables. The upper 95% confidence intervals for the differences between 349 
outcome variable treatment means were less than + Delta for GCMPS, VASi and 350 
VASs, thus establishing non-inferiority for each of these outcome variables.  As can 351 
be seen from Table 2 and in Figure 5 the lower 95% confidence interval for the 352 
difference in MNT is below - Delta, indicating that non-inferiority was not 353 
demonstrated, however, the very large standard error of the difference indicates that 354 
with only 11  dogs remaining in the meloxicam group and 30 in the paracetamol group 355 
due to missing values the study had little power remaining to identify non-inferiority, or 356 
otherwise, given the variability in MNT scores within treatments.357 
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Table 2. The results of the non-inferiority analysis of all outcome measures, showing no difference in variance between treatments 358 
(Levene’s test) and no significant difference between treatments (2-tailed t-test). The treatment means and their difference are 359 
shown together with the 95% confidence interval for the difference between the means. Note that the VAS sedation scores are 360 
natural log transformed (ln(x + 0.1)) to satisfy the assumption of a normal distribution. For each outcome variable, the LCI and UCI 361 
of the difference sit within ± Delta, demonstrating non-inferiority, at each of the given Deltas with the exception of MNT. The delta 362 
for VASs of 20.0 becomes 3.0 on the natural log scale. 363 
 364 
 365 
 Levene’s  Test  t-test    Diff.  between means   
   F p t df p (2-tail) Paracet. 
(SE) 
Melox. 
(SE) 
Mean diff. SE diff. LCI UCI Delta 
GCPS 0.041 0.840 0.691 68 0.492 1.2542 
(0.12) 
1.1081 
(0.18) 
0.1462 0.21162 -0.2761 0.5684 3 
MNT 0.465 0.499 -1.323 39 0.193 80.461 
(5.42) 
94.835 
(10.20) 
-14.374 10.8622 -36.345 7.5968 10 
VAS infl. 1.428 0.239 -0.123 39 0.903 13.431 
(0.63) 
13.574 
(1.11) 
-0.1430 1.16722 -2.5039 2.2179 20 
LnVAS sed. 0.000 0.995 -0.570 68 0.570 -0.3419 
(0.16) 
-0.1873 
(0.22) 
-0.1582 0.27738 -0.7117 0.3953 3 
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Rescue analgesia and concomitant treatments 366 
Six dogs (three in group M (12.5%) and three in group P (6.5%) had scores equal to 367 
or higher than 6/24 and therefore received one dose of methadone as a rescue 368 
analgesic.  369 
In group P one dog received acepromazine (0.01mg kg-1) after recovery to treat 370 
nervous temperament and excessive barking. One bolus of fentanyl at 1 to 5 µg kg-1 371 
IV was administered during the surgery in two dogs, one in the group M (4%) (with 372 
TTA procedure) and one in the group P (2%) (undergoing surgery to correct 373 
Brachycephalic Obstructive Airway Syndrome). In group M one dog required 374 
additional analgesia during the surgery and mistakenly received methadone (0.1mg 375 
kg -1) IV instead of fentanyl. 376 
 377 
Tolerability 378 
Two dogs (8%) in group M had adverse effects that could potentially be attributable to 379 
the test drug. These dogs were removed from the study, but data were collected until 380 
the adverse event and included in the analysis. After the adverse event pain 381 
assessments were performed to ensure post-operative comfort of the patient. One of 382 
the dogs, undergoing a hind limb nodulectomy had diarrhoea at T12 and another having 383 
a TTA procedure regurgitated at T12. A dog in group P (2%), undergoing a TECA, had 384 
one episode of regurgitation at T4. As this dog had a history of regurgitation prior to 385 
anaesthesia, the clinician did not consider this related to the treatment drug and this 386 
dog was kept in the study. However, this episode cannot be excluded as a possible 387 
adverse effect of paracetamol/codeine. No other adverse effects attributable to test 388 
drug administration were found in group P and there were no significant differences 389 
between groups. 390 
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 391 
Discussion 392 
The key finding from this study was that paracetamol/codeine provides non-inferior 393 
analgesia to meloxicam in dogs undergoing surgery when combined with 394 
buprenorphine given for the first 24 hours after surgery and methadone for 395 
premedication. Pain scores were low over the period of assessment and requirement 396 
for rescue analgesia was low in both groups of dogs. In veterinary medicine NSAIDs 397 
are commonly used for post-operative analgesia in dogs. There is supporting evidence 398 
for meloxicam efficacy in controlling pain and inflammation in dogs undergoing surgery 399 
and therefore sufficient evidence for it to be used as a positive control for this study 400 
[1,2].  401 
Methadone was given as premedication to provide an adequate and rapid onset of 402 
analgesia for surgery. Methadone was combined with a non-analgesic sedative 403 
(acepromazine or midazolam) to avoid confounding factors on the postoperative pain 404 
assessments. 405 
 406 
The GCMPS-SF has been validated for the quantification of surgical pain in dogs 407 
[13], however, it is not entirely specific to pain and may be biased by concurrent 408 
sedation in the postoperative period [14]. To minimize the confounding factor of 409 
sedation, a VASs was also used to score sedation. The sedation scores in both 410 
groups decreased postoperatively but the difference between them was not 411 
significantly different and sedation scores were low during the time period over which 412 
pain was quantified.  413 
 414 
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Mechanical nociceptive threshold was also measured frequently. Post operative 415 
MNTs were numerically slightly lower in the paracetamol group, although the 416 
differences did not reach statistical significance because MNT was too variable 417 
within treatments to give sufficient power to detect non-inferiority. These variations 418 
were likely to be due primarily to the lower anti-inflammatory effect of paracetamol or 419 
lower analgesic efficacy compared to meloxicam [3], but also may be due to 420 
differences between individual dogs, as individual skin thickness, blood flow or 421 
distribution of the nociceptors, may affect the peripheral perception of stimuli [15] 422 
and are not easily controlled [11]. Mechanical hyperalgesia has been reported in 423 
dogs post-surgery using unimodal [16] and multimodal [17] analgesic strategies, as 424 
was utilised in this study.  425 
 426 
The range of surgical procedures, and inclusion of different surgeons with variable 427 
experience between them are likely to add confounding factors influencing post-428 
operative recovery and pain. However, an advantage of this study was that the 429 
orthopaedic surgeries were all performed by the same experienced surgeon. Further 430 
studies restricting recruitment to a single type of surgery and a single surgeon in all 431 
cases would be expected to have increased the power of a study. 432 
 433 
Although paracetamol/codeine was found to be non-inferior to meloxicam in this study, 434 
it should be considered that the licenced formulation of oral paracetamol/codeine in 435 
the UK is recommended to be given three times daily, as opposed to meloxicam which 436 
is administered once daily. This may be associated with poor compliance with 437 
paracetamol/codeine treatment and therefore inadequate post-operative pain 438 
management. 439 
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 440 
This study had several limitations. No power calculation was performed because there 441 
were no prior data on which to base a sample size calculation, which was not ideal. 442 
However, a non-inferiority trial is a ‘through the looking glass’ reversal of the more 443 
familiar superiority trial, and a lack of power would lead to non-inferiority not being 444 
established;  for example, because the mean difference was not estimated accurately 445 
enough, this leads to a wide confidence interval which would be more likely to overlap 446 
a chosen Delta. The chosen Delta values were non validated and it could be argued 447 
were somewhat arbitrary although they were selected based on what was considered 448 
to be clinically relevant differences between groups. Therefore the selection of Delta 449 
and the fact that it was non validated could also be considered a limitation of the study. 450 
 451 
The primary objective of the study was to assess and compare perioperative efficacy 452 
of oral paracetamol/codeine and meloxicam. Initially, it was planned to assess dogs 453 
for a 72 hours study period; however, it was considerably more difficult to obtain owner 454 
consent for prolonged hospitalization rather than for 48 hours. Another limitation to a 455 
prolonged hospitalization was obtaining good compliance from the surgeons involved 456 
in the study, a problem common within large institutions with a heavy workload. At the 457 
end of the 48 hour assessment period dogs in the paracetamol/codeine group were 458 
switched to treatment with meloxicam. The time period that should be allowed when 459 
switching between NSAIDs is debatable with no clear consensus on an adequate 460 
“wash-out” period. Paracetamol is anecdotally believed to have less side effects than 461 
traditional NSAIDs and has been recommended as a “bridging treatment” during the 462 
wash out period between two traditional NSAIDs. Therefore it was considered 463 
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acceptable to switch from paracetamol/codeine to meloxicam without a “wash-out” 464 
period for continued analgesia after the end of the study. 465 
 466 
Buprenorphine was used in addition to the test drug. The small number of dogs that 467 
required rescue analgesia may reflect that a premedication with methadone, pre-468 
surgical administration of oral paracetamol/codeine or meloxicam and buprenorphine 469 
at extubation was sufficient to control post-operative pain and inflammation in most 470 
dogs. However, it is also recognised that the use of buprenorphine in the first 24 hours 471 
may be a confounding factor for the post-operative assessments because the use of 472 
paracetamol/codeine and meloxicam alone were only compared between 24 and 48 473 
hours after surgery. However, this protocol mimics the reality of practice as the 474 
majority of surgeons use buprenorphine as part of a multimodal analgesia protocol for 475 
the postoperative recovery of patients [18,19].  476 
 477 
Data were collected at two study centres, Langford Vets, University of Bristol  and St. 478 
David’s Veterinary Group, Exeter. Collecting data from two centres increased the 479 
case recruitment, as St. David’s Veterinary Group is a very busy practice with a high 480 
daily case load. In addition, a loco-regional anaesthesia / analgesia protocol is 481 
common practice for orthopaedic procedures at Langford Vets, which would have 482 
confounded the concurrent assessment of analgesic efficacy of the test drugs, 483 
whereas it was not standard practice at St. David’s Veterinary Group at the time that 484 
the study was carried out. To minimize the effects of an inevitable increase in the 485 
number of people dealing with cases from two centres, anaesthesia was 486 
standardized and outcome scoring measures were always performed by the same 487 
assessor who was blinded to treatment group. 488 
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 489 
Data were missing from some assessments, mainly due to the impossibility of 490 
measuring MNT and VASi in patients that required bandages or casts post-surgically, 491 
however, all other assessments were performed with the same frequency.  492 
 493 
In group M one dog required additional analgesia during the surgery and mistakenly 494 
received methadone (0.1mg kg -1) IV instead of fentanyl. This treatment in a single 495 
dog is unlikely to have impacted upon the overall findings of the study.  496 
 497 
It should be considered that averaging across time simplifies the analysis at the 498 
expense of losing the longitudinal information. It might be the case that the treatments 499 
differ in how they relieve pain, e.g. one having a more immediate effect than the other. 500 
However, this does not seem to be the case in the present study given the change in 501 
pain score over time represented graphically. 502 
 503 
The order of the assessments could have been improved so that sedation was 504 
assessed first, followed by the GCMPS-SF. This would have allowed us to assess 505 
whether a dog was too sedated to meaningfully administer the GCMPS-SF scoring 506 
system. However, all dogs were fully recovered from anaesthesia by the 2 hour time 507 
point post extubation when pain assessments commenced. Using visual analogue 508 
scales for sedation and inflammation has a number of disadvantages; they are 509 
unvalidated and can be subject to significant intra-observer variability. Since the study 510 
was carried out a composite sedation scale has been published which has undergone 511 
a degree of validation [20], however, this was not available at the time that the study 512 
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was carried out. There are no validated scales to assess inflammation in dogs post-513 
operatively. 514 
 515 
The lack of significant difference between paracetamol/codeine and meloxicam in 516 
our study could be because both test drugs are similarly effective or ineffective. The 517 
distinction is difficult to make without the inclusion of a placebo group. However, the 518 
inclusion of a group receiving placebo and undergoing surgery cannot be considered 519 
ethical and therefore was not included as part of the study design. 520 
 521 
This study suggests that meloxicam and paracetamol/codeine can be used in dogs 522 
to provide similar effects in the post-operative period. Although paracetamol has 523 
been used for many years to control pain in dogs, there was paucity of data to prove 524 
its efficacy on the post-operative period. We have demonstrated that 525 
paracetamol/codeine is non inferior to meloxicam in the postoperative period within 526 
the context of the peri-operative analgesia regimen (methadone premedication, 527 
buprenorphine for the first 24 hours after surgery) carried out for this study.  528 
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 599 
Figure legends 600 
 601 
Figure 1: Mean Glasgow Composite Pain Scores throughout the study duration in dogs 602 
administered paracetamol and meloxicam. Error bars indicate SEM. N= 24 in the 603 
meloxicam group and 46 in the paracetamol group. 604 
 605 
Figure 2: Mean percentage change (normalised to the baseline value) in mechanical 606 
nociceptive threshold throughout the study duration in dogs administered paracetamol 607 
and meloxicam. Error bars indicate SEM. N= 13 in the meloxicam group and 28 in the 608 
paracetamol group. 609 
 610 
Figure 3: Mean Visual Analogue Scale for sedation (VASs) scores throughout the 611 
study duration in dogs administered paracetamol and meloxicam. Error bars indicate 612 
SEM. N= 24 in the meloxicam group and 46 in the paracetamol group. 613 
 614 
Figure 4: Mean Visual Analogue Scale for inflammation (VASi) scores throughout the 615 
study duration in dogs administered paracetamol and meloxicam. Error bars indicate 616 
SEM. N= 13 in the meloxicam group and 28 in the paracetamol group. 617 
 618 
Figure 5. Graphs showing for each of the outcome variables the mean difference 619 
between the hourly averaged outcome score,  together with a 95% confidence interval 620 
for the difference. Broken, vertical lines on the graphs show ± Delta. The difference 621 
was calculated as Paracetamol treatment minus Meloxicam treatment. Thus, with the 622 
exception of MNT, as superior treatments have lower values, negative values for the 623 
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difference indicate greater efficacy with Paracetamol and positive values greater 624 
efficacy with Meloxicam, and vice versa for MNT. For non-inferiority to be shown, the 625 
upper 95% confidence limit for the difference should be below + Delta, and for MNT 626 
the lower 95% confidence limit would have needed to have been greater than - Delta. 627 
 628 
 629 
 630 
 631 
